CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：125

作者：

Maisey, NR ^{[1
]}

Norman, AR ^{[1
]}

Hill, A ^{[1
]}

Massey, A ^{[1
]}

Oates, J ^{[1
]}

Cunningham, D ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期

关键词：

pancreatic cancer; CA19-9; prognosis; chemotherapy;

D O I：

10.1038/sj.bjc.6602760

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).

引用

页码：740 / 743

页数：4

共 18 条

[1] DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma [J].

Biankin, AV ;

Morey, AL ;

Lee, CS ;

Kench, JG ;

Biankin, SA ;

Hook, HC ;

Head, DR ;

Hugh, TB ;

Sutherland, RL ;

Henshall, SM .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4531-4542

[2] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[3]

COX DR, 1972, J R STAT SOC B, V34, P187

[4] Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis [J].

Fujimoto, K ;

Hosotani, R ;

Wada, M ;

Lee, JU ;

Koshiba, T ;

Miyamoto, Y ;

Tsuji, S ;

Nakajima, S ;

Doi, R ;

Imamura, M .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (09) :1439-1447

[5] EVALUATION OF THE UTILITY OF A RADIOIMMUNOASSAY FOR SERUM CA-19-9 LEVELS IN PATIENTS BEFORE AND AFTER TREATMENT OF CARCINOMA OF THE PANCREAS [J].

GLENN, J ;

STEINBERG, WM ;

KURTZMAN, SH ;

STEINBERG, SM ;

SINDELAR, WF .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :462-468

[6] Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? [J].

Gogas, H ;

Lofts, FJ ;

Evans, TRJ ;

Daryanani, S ;

Mansi, JL .

BRITISH JOURNAL OF CANCER, 1998, 77 (02) :325-328

[7]

Halm U, 2000, BRIT J CANCER, V82, P1013

[8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[9] Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy [J].

Katz, A ;

Hanlon, A ;

Lanciano, R ;

Hoffman, J ;

Coia, L .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (02) :393-396

[10] COLORECTAL-CARCINOMA ANTIGENS DETECTED BY HYBRIDOMA ANTIBODIES [J].

KOPROWSKI, H ;

STEPLEWSKI, Z ;

MITCHELL, K ;

HERLYN, M ;

HERLYN, D ;

FUHRER, P .

SOMATIC CELL GENETICS, 1979, 5 (06) :957-972

← 1 2 →